Back to Search Start Over

Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial

Authors :
Kelly, Peter
Weimar, Christian
Lemmens, Robin
Murphy, Sean
Purroy, Francisco
Arsovska, Anita
Bornstein, Natan M.
Czlonkowska, Anna
Fischer, Urs
Fonseca, Ana Catarina
Forbes, John
Hill, Michael D.
Jatuzis, Dalius
Kõrv, Janika
Kruuse, Christina
Mikulik, Robert
J Nederkoorn, Paul
O’Donnell, Martin
Sandercock, Peter
Tanne, David
Tsivgoulis, Georgios
Walsh, Cathal
Williams, David
Zedde, Marialuisa
Price, Christopher I.
Kelly, Peter
Weimar, Christian
Lemmens, Robin
Murphy, Sean
Purroy, Francisco
Arsovska, Anita
Bornstein, Natan M.
Czlonkowska, Anna
Fischer, Urs
Fonseca, Ana Catarina
Forbes, John
Hill, Michael D.
Jatuzis, Dalius
Kõrv, Janika
Kruuse, Christina
Mikulik, Robert
J Nederkoorn, Paul
O’Donnell, Martin
Sandercock, Peter
Tanne, David
Tsivgoulis, Georgios
Walsh, Cathal
Williams, David
Zedde, Marialuisa
Price, Christopher I.
Source :
Kelly , P , Weimar , C , Lemmens , R , Murphy , S , Purroy , F , Arsovska , A , Bornstein , N M , Czlonkowska , A , Fischer , U , Fonseca , A C , Forbes , J , Hill , M D , Jatuzis , D , Kõrv , J , Kruuse , C , Mikulik , R , J Nederkoorn , P , O’Donnell , M , Sandercock , P , Tanne , D , Tsivgoulis , G , Walsh , C , Williams , D , Zedde , M & Price , C I 2021 , ' Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial ' , European Stroke Journal , vol. 6 , no. 2 , pp. 222-228 .
Publication Year :
2021

Abstract

Background: Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events. Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone. Design: CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5 mg/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40 years, with non-severe ischaemic stroke (modified Rankin score ≤3) or high-risk TIA (ABCD2 > 3, or positive DWI, or cranio-cervical artery stenosis) within 72 hours-28 days of randomisation, with qualifying stroke/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median follow-up will be 36 months. The primary analysis will be by intention-to-treat. Outcome: The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal). Summary: CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke. Schedule: First-patient first-visit was December 2016. Recruitment to complete in 2021, follow-up to complete in 2023.

Details

Database :
OAIster
Journal :
Kelly , P , Weimar , C , Lemmens , R , Murphy , S , Purroy , F , Arsovska , A , Bornstein , N M , Czlonkowska , A , Fischer , U , Fonseca , A C , Forbes , J , Hill , M D , Jatuzis , D , Kõrv , J , Kruuse , C , Mikulik , R , J Nederkoorn , P , O’Donnell , M , Sandercock , P , Tanne , D , Tsivgoulis , G , Walsh , C , Williams , D , Zedde , M & Price , C I 2021 , ' Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial ' , European Stroke Journal , vol. 6 , no. 2 , pp. 222-228 .
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1322766756
Document Type :
Electronic Resource